According to the Q&A session at the Q1 2016 webcast, Mike Sweeney indicated that there will be a sample size estimate analysis at 175 MACE events, at which time the trial could be adjusted to continue until 375 MACE events. I do not know how many more patients they would need to add, how much this will cost, or how long it will extend the trial. I kind of remember Sweeney indicating that it would be increased to 3600 patients, but I can't find that statement in my notes.

BDAZ